FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Pesquisa/Paper
Voltar à Biblioteca de Pesquisa
PubMedReviewSujeitos Humanos

Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study.

Mattingly T Joseph, Duru Emeka Elvis, Conti Rena M
Health affairs scholar2026DOI: 10.1093/haschl/qxag023
GLP-1 receptor agonistsglucagon-like peptide-1

Nota de Qualidade

6/10

Citações

0

Sujeitos

Humano

Análise da Peptide Contacts

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of GLP-1 receptor agonists, glucagon-like peptide-1 in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Decent human data on GLP-1 receptor agonists, glucagon-like peptide-1. Not the final word, but a meaningful data point that adds to the weight of evidence.

Encontros-chave

The study found that GLP-1 receptor agonists were associated with a higher incidence of administration-related adverse events compared to insulin, particularly after supply shortages began in late 2022. The increase in reports was linked to both increased utilization and potential dosing errors.

Limitações

The study relies on voluntary reporting data which may not capture all adverse events accurately, lacks exposure denominators for risk assessment, and does not account for changes in prescribing patterns or patient behavior over time.

Como Interpretar Esta Pesquisa

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Análise da Peptide Contacts

Highlighting the safety concerns and educational needs surrounding the use of GLP-1 receptor agonists in clinical practice.

GLP-1 receptor agonistsglucagon-like peptide-1

GLP-1 Receptor Agonists: Safety Concerns and Patient Education Needs Highlighted

Published: May 16, 2026 | Source: Health affairs scholar (2026) | Category: GLP-1 receptor agonists, glucagon-like peptide-1

Overview

A new study published in Health Affairs Scholar has revealed that the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with a higher incidence of administration-related adverse events compared to insulin. This finding underscores the importance of patient and provider education, especially as supply shortages have affected availability.

Study Background

GLP-1 receptor agonists are increasingly used in clinical practice for their benefits in managing type 2 diabetes and obesity. However, concerns about safety issues have grown alongside their rapid adoption. Researchers sought to understand the nature and extent of adverse events reported through the FDA's Adverse Event Reporting System (FAERS) between January 2015 and December 2024.

What the Research Found

The study analyzed over 112,000 reports in FAERS data, focusing on GLP-1 receptor agonists and injectable insulin products. Key findings include:

  • Higher Incidence of Administration-Related Events: Among reported adverse events, GLP-1s were associated with a higher share (63%) of administration-related reactions compared to insulin (39%).
  • Increased Reports Post-Supply Shortages: The number of reports involving dosing issues and administration errors for GLP-1 receptor agonists increased significantly starting in Q4 2022, coinciding with national supply shortages.
  • Potential Impact of Increased Utilization: While the study suggests that some increase in reporting volume may reflect higher utilization rather than increased risk due to lack of exposure denominators, it highlights the need for ongoing surveillance.

What This Means for Peptide Users

The findings indicate a critical need for enhanced patient education and provider training on proper administration techniques. Patients using GLP-1 receptor agonists should be vigilant about dosing accuracy and seek guidance from healthcare providers if they encounter difficulties or adverse reactions. Providers are encouraged to closely monitor patients, especially during periods of supply shortages.

Limitations and Caveats

The study relies heavily on voluntary reporting data, which may not capture all adverse events accurately. Additionally, the lack of exposure denominators complicates risk assessment. The analysis also does not account for changes in prescribing patterns or patient behavior over time, which could influence reported outcomes.

How This Compares to Previous Research

Previous studies have highlighted potential side effects and safety concerns associated with GLP-1 receptor agonists but did not focus specifically on administration-related issues. This study provides a more detailed analysis of adverse events during the period of supply shortages, offering new insights into patient education needs and regulatory considerations.

Our Analysis

PeptideVault's assessment suggests that while this study highlights important safety concerns related to GLP-1 receptor agonists, it also underscores the need for ongoing research and surveillance. The findings are valuable in guiding clinical practice but should be interpreted with caution due to limitations inherent in voluntary reporting systems.

Key Takeaways

  • Enhanced Patient Education: Providers must ensure that patients understand proper administration techniques.
  • Regulatory Attention Needed: Continued regulatory oversight is essential, especially during periods of supply shortages.
  • Ongoing Surveillance: Post-marketing surveillance remains crucial for monitoring safety signals and adjusting clinical guidelines as necessary.

Original Source

Citation: Mattingly T Joseph, Duru Emeka Elvis, Conti Rena M (2026). Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study.. Health affairs scholar. DOI: 10.1093/haschl/qxag023

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota do Editor

Esta análise foi escrita pela equipe de pesquisa da Peptide Contacts para tornar achados complexos acessíveis à comunidade de peptídeos. Encorajamos os leitores a revisar o paper original para metodologia e dados completos. Para mais sobre GLP-1 receptor agonists, explore nossas guias de pesquisa.

Citação

Mattingly T Joseph, Duru Emeka Elvis, Conti Rena M. (2026). Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study.. Health affairs scholar. https://doi.org/10.1093/haschl/qxag023

Visualize o texto completo em PubMed

Papers Relacionados

Explore Mais

Este conteúdo é derivado de pesquisas revisadas por pares para fins educativos apenas. Não constitui conselhos médicos. Sempre consulte um provedor de saúde qualificado antes de usar qualquer terapia baseada em peptídeos.